Splenic lymphoma with villous lymphocytes (SLVL) is a B cell chronic lymphoproliferative disorder. Splenectomy and/or chlorambucil are usually regarded as the most effective treatment in SLVL patients. However, a few patients relapse and the second-line treatment remains questionable. In a retrospective study, we evaluated the efficacy and toxicity of fludarabine (FDR) in 10 SLVL patients. The median duration between diagnosis and treatment was 17 months (range, 1-30). Two patients were previously untreated. The patients received FDR 25 mg/m 2 /day by venous infusion for 5 days with a median of four cycles of chemotherapy (range, 2-6). All patients were assessable: five patients achieved a good and persistent response after a median follow-up of 14 months (5-31), two achieved a good response but relapsed after a follow-up of 15 and 36 months. One out of the three partial responders have a persistent response. The treatment was well tolerated. FDR appears to be an efficient therapy with a favorable toxicity profile for patients in relapse after splenectomy or resistant to CLB. Furthermore it could constitute an alternative to splenectomy in older patients. A longer follow-up and the study of a larger group of patients are warranted to confirm our findings. Leukemia (2000) 14, 573-575.
Introduction
Splenic lymphoma with villous lymphocytes (SLVL) has been recognized as a distinct clinico-pathological entity, but could represent a variant of marginal zone lymphoma.
1 SLVL is usually an indolent mature B cell lymphoproliferative disorder (B-CLD). The main characteristics are the presence of massive splenomegaly and absolute lymphocytosis with a high number (Ͼ30%) of circulating villous lymphoid cells (VL). A variable degree of anemia and/or thrombocytopenia may also be present. The diagnosis can, however, be difficult to make on morphological criteria, especially in patients without absolute lymphocytosis. [2] [3] [4] In such cases, immunologic profile may be indicative of SLVL. Indeed the lymphocytosis is of B cell type reacting with CD19, CD20, CD22, CD24 antigens. In 80% of cases, no reactivity was found with CD5. In some cases, mostly CD5-negative and DBA44-positive, differential diagnosis with hairy cell leukemia (HCL) may be difficult and CD103 expression could help to distinguish both. 5 Splenectomy or alkylating drugs such as chlorambucil (CLB) or cyclophosphamide are regarded as the most effective treatment, particularly in patients with symptomatic splenomegaly, rapid increase of lymphocyte or severe pancytopenia. 4, 6 However, splenectomy sometimes carries surgical risks, CLB is often not efficient and relapse is frequent. Fludarabine (FDR) is a purine analogue, which can induce a good response in a substantial proportion of patients with B-CLD. 7, 8 However, its use has rarely been reported in SLVL. 9 We evaluated, in a retrospective study, FDR treatment, either as a first-or second-line therapy in 10 SLVL patients.
Patients and methods
From 1994 to 1998, 10 SLVL patients, five males and five females, with a median age of 59 years (range, 37-74), were selected for FDR therapy. Two patients received FDR as a firstline therapy and eight as a second-line therapy. Nine patients had massive splenomegaly at diagnosis. SLVL may not be a single entity and includes a variety of indolent B cell tumors that display a propensity for spleen and marrow infiltration. The diagnosis of SLVL was confirmed if a high number of VL was detected on peripheral blood films, using criteria identical to those previously described. 2, 4 Morphological assessment was performed by two independent reviewers, without knowledge of the immunophenotype findings. The abnormal lymphoid cells expressed CD19, CD20, CD22, CD24, and FMC7. In contrast, CD5, B-ly-7 and HC2 expression was negative in all cases. 5 The median time from diagnosis to FDR therapy was 17 months (range, 1-30).
Two patients were not previously treated (Nos 8 and 9), two were splenectomized with a transient response for a duration of 6 and 11 months, respectively (Nos 5 and 7). Six patients received chemotherapy: chlorambucil (CLB), cyclophosphamide or CHOP regimen with transient success in only two cases (Table 1) . One patient received recombinant alpha interferon over 6 months without any response (No. 6). All patients were free of active infection and available for follow-up evaluation. Reasons and indications of FDR therapy for each patient are indicated in Table 1 .
Eight patients received four monthly courses at a daily dose of 25 mg/m 2 during 5 days. Two patients (Nos 5 and 9) received two and six courses, respectively (Table 2) . Patients treated by FDR received oral prophylaxis by sulfamethoxazole.
Response to therapy was assessed as follows: a good response (GR) was defined as the disappearance of splenomegaly, the absence of symptoms and a platelet count superior to 100 × 10 9 /l, absolute neutrophil count (ANC) Ͼ1 × 10 9 /l, hemoglobin level superior to 10 g/dl without blood transfusion, and the absence of blood circulating VL.
A partial response (PR) was defined by at least a 50% reduction in splenomegaly, with a persisting organomegaly and by improvement in blood hematological parameters over baseline but ANC inferior to 1 × 10 9 /l, platelet count inferior to 100 × 10 9 /l or hemoglobin level inferior to 10 g/dl, persisting 2 months after FDR therapy. Failure was defined as a persistent or progressive increase in the number of peripheral blood VL and/or splenomegaly. Relapse was defined as a progressive increase in the number of peripheral blood VL and/or increasing splenomegaly after an initial good or partial response. Spleen sizes were evaluated before and after FDR therapy by physical examination and CT scan. Bone marrow examination was not systematically performed after treatment. Follow-up was assessed by physical evaluation, CT scan and peripheral blood examination every 4 months.
Results
All 10 patients were assessable for response and toxicity. Five patients achieved a good response which was maintained during a median follow-up of 14 months (range, 5+ to 31+). Two patients achieved a CR but relapsed after 15 and 36 months, respectively. Three patients achieved a partial response: two relapsed 10 months and 18 months later, respectively, and were splenectomized, one remained stable after 13 months of follow-up. No failure was observed ( Table 2 ). The response was progressively obtained after each FDR cycle. A maximal response was observed after three cycles for seven patients, four cycles for two patients and six cycles for one (No. 6). No severe clinical side-effect was noted during and after FDR therapy except for patient No. 5 who presented transient facial paralysis at the beginning of the third FDR course (chemotherapy was definitively stopped and neurologic symptoms disappeared) and for patient No. 6 who presented transient resolute auto-immune hemolytic anemia after six courses of FDR. Two other patients presented transient severe neutropenia (neutrophils Ͻ0.5 × 10 9 /l) but no documented infections were observed and no blood support was required except for patient No. 4 who needed transient packed red blood cell (RBC) transfusion. No others toxicities were observed. All the patients remained alive, except patient No. 5 who died from infectious complications after relapse and a new therapy by 2-chloro-deoxyadenosine. No FDR dose reduction was performed.
Discussion
SLVL has a relatively benign clinical course. However, a few patients could require treatment, because of a symptomatic splenomegaly, an increase in the number of blood VL or severe cytopenia. The aim of this study was to evaluate the impact of FDR on clinical symptomatic splenomegaly and/or hematological peripheral blood disorders from SLVL patients. In our study, all patients were responders to FDR with seven and three good and partial prolonged responses obtained, respectively. Patients with only partial response after four courses may benefit from two additional courses. For example, patient No. 6 exhibited a progressive response after each of the first four courses and two more cycles resulted in a good response.
In a previous series of 50 patients a 3-year overall survival of 82% was observed. 6 Out of the 50 SLVL patients, splenectomy was performed in 20 patients. One patient died of a post-operative complication at 6 weeks, and 19 patients were good responders. Two patients relapsed with aggressive disease 2 years after splenectomy: the good response was sustained in the 17 patients for a median of 4 years (6 months-7 years). The response to chemotherapy was poor: in 18 patients treated in first line, only eight were good responders and 10 patients had minor or no response.
In our previous study, the 5-year overall survival rate was 78% in a large series of 100 patients with SLVL. Only 15 patients died from progressive disease or related treatment complications. Twenty-one of 28 (75%) splenectomized patients had good partial response but 7/23 (30%) relapsed. 4 The results after chemotherapy are similar to Mulligan's in which 10 out of 19 patients are good partial responders and nine exhibit minimal or no response. 4 We identified a subgroup of SLVL patients with a poor prognosis. The patients with a leukocyte count Ͼ30 × 10 9 /l or initially treated with chemotherapy had significantly lower overall survival than other patients. 4 A relapse or a failure after splenectomy and/or chemotherapy could be a difficult challenge. FDR is recognized as a drug with promising activity in a variety of B-CLD. 7, 8 Although fludarabine was evaluated in patients with chronic lymphoid leukemia (CLL) and HCL, the experience of purine analogues in the treatment of SLVL is limited. Bolam et al 9 reported four cases of resistant or relapsing SLVL successfully treated by FDR with a lasting good response for two of them, the other two died from unrelated diseases.
The main complications from treatment of CLL with purine analogues are bone marrow depression resulting in cytopenia, immune suppression which can lead to infections, and immune deregulation with auto-immune hemolytic anemia. We observed no severe clinical toxic side-effect, except one case of transient facial paralysis and one case of auto-immune hemolytic anemia cured after steroid therapy. Bolam et al 9 
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reported no significant side-effect for the four patients treated by FDR with prophylactic ciprofloxacin administration to cover periods of severe neutropenia.
Within the limits of our study, FDR therapy for SLVL is safe, with no opportunistic complications observed during followup with a prophylaxy by oral sulfamide.
In conclusion, our results suggest that FDR could be an interesting choice of therapy for patients in relapse after splenectomy or resistant to CLB. Furthermore it could constitute an alternative to splenectomy for older patients. A number of four FDR courses seems necessary for an optimal response. However, the schedule would entirely depend on the clinical response. A longer follow-up and a larger group of patients are warranted to confirm our findings.
